Aston University

Galimedix Therapeutics starts Phase 1 trial of oral GAL-101, an amyloid beta aggregation modulator. Myopia control in 2034 may involve DIMS lenses, developed by Carly Lam. Tenpoint and Visus Therapeutics merge, focusing on presbyopia and cataracts. DOT 0.2 lenses show effectiveness in myopia control. Demodex blepharitis diagnosis and treatment are crucial in dry eye management.

OpenAI's ChatGPT, launched in 2022, has seen significant developments including GPT-4 and o1 models, SearchGPT, and internal challenges. For 2025, OpenAI aims for ChatGPT to perform tasks independently, potentially as an autonomous agent. Future releases like Orion and a 100x more powerful model are anticipated. OpenAI may also consider scaling down to less resource-intensive, specialized models.

xWave Technologies secures UK NHS contract, NWEH pilots clinical trial recruitment model, Ada Health partners with Groupe Mutuel, Aston University develops predictive assisted living system, Betsi Cadwaladr UHB upgrades infrastructure, mental health data map reveals challenges in young people, UK report on AI assurance market, and upcoming NHS IT Infrastructure 2024 event.

Aston University researcher, Professor Igor Meglinski, developed a technique using Orbital Angular Momentum (OAM) light, which could revolutionize non-invasive diagnostics and optical communication. OAM light retains phase characteristics through scattering media, enabling detection of small changes in refractive index with high accuracy, potentially eliminating invasive procedures like surgery or biopsies. The research, published in Nature journal Light Science & Application, opens possibilities for advanced biomedical applications and secure optical communication systems.

Most people with food allergies and caregivers of affected children experience psychological distress, primarily due to fear of anaphylaxis. Only 20% have been assessed for anxiety. Cost is a significant barrier to seeking psychological support.

Aston Institute for Membrane Excellence (AIME) launched at Aston University with a £10 million grant, focusing on collaborative science across biology, chemistry, physics, and engineering. AIME aims to develop biomimetic membranes for water purification, therapeutic nanoparticles, and drug target identification, emphasizing interdisciplinary collaboration.

Aston University and Alpharmaxim developed the world’s first evidence-based behaviour change tool, H-BIT, to support new drug adoption for rare and complex diseases, revolutionizing drug launch campaigns and positioning Alpharmaxim as a leader in behaviour change.

The 'Navigating EU and FDA Regulations for Drug/Device and Device/Drug Combination Products Training Course' aims to help participants understand and navigate the complex regulatory landscape for such products in the EU and USA, ensuring compliance and successful commercialization.

The 'Navigating EU and FDA Regulations for Drug/Device and Device/Drug Combination Products Training Course' aims to help participants understand the regulatory frameworks for these products in the EU and USA, offering practical guidance on Notified Body expectations, clinical trial considerations, and post-market surveillance. The course is designed for development and regulatory personnel in the medical device, pharmaceutical, and diagnostic industries.